RxDoctor Payments Data

Phillip Delio, MD

Neurology · Santa Barbara, CANPI 1255358156

Payments from drug & device makers

$154,194in general payments, 2019–2025

Across 250 payments — averaging $616.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$94K
  • Bayer$21K
  • Biohaven Pharmaceuticals, Inc.$19K
  • Biohaven Pharmaceutical Holding Company Ltd.$7K
  • W. L. Gore & Associates, Inc.$5K
  • Biogen$3K
  • plus $6K from 18 others

What the payments were for

  • Consulting fees$4,2903%
  • Speaking & faculty fees$115,03687%
  • Travel & lodging$5,9755%
  • Food & beverage$6,0705%
  • Education$4220%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$154,194 in reported general payments places this provider in the 90th percentile of 1,996 neurology providers in California.

See all neurology providers in California

Medicare billing

Part B allowed, 2024
$814,517
Medicare patients
1,035
Services billed
80,648

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Nurtec OdtRimegepant Sulfate123$191,842
AustedoDeutetrabenazine13$171,291
OctagamImmun Globg(Igg)/Malt/Iga Ov5013$154,089
Aimovig AutoinjectorErenumab-Aooe124$135,810
UbrelvyUbrogepant81$95,886
Teriflunomide34$74,404
QuliptaAtogepant46$51,835
NeuproRotigotine55$50,868
BriviactBrivaracetam24$45,227
BotoxOnabotulinumtoxina16$25,511
Emgality PenGalcanezumab-Gnlm26$23,637
Pyridostigmine Bromide ErPyridostigmine Bromide11$15,038
RytaryCarbidopa/Levodopa12$13,014
Memantine Hcl326$10,874
Carbidopa-LevodopaCarbidopa/Levodopa368$10,548

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerNurtec Odt, Octagam$30$345,931136 claims
AbbVieUbrelvy, Qulipta, Botox$93,594$173,232143 claims
Teva Pharmaceuticals USA, Inc.Austedo$296$171,29113 claims
UCB, Inc.Neupro, Briviact$13$96,09579 claims
Amneal Pharmaceuticals LLCRytary, Pyridostigmine Bromide$1,515$18,28269 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,996 neurology providers in California.

Other neurology in Santa Barbara

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →